# Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

> **NCT04805983** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 36 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** BMS-984923

## Key facts

- **NCT ID:** NCT04805983
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2022-04-24
- **Final completion:** 2022-04-24
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805983, "Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04805983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*